Dal Lago Marco sold $85K of STVN

Dal Lago Marco (Chief Financial Officer) sold 4,209 shares of Stevanato Group S.p.A. (STVN) at $20.09 on 2026-08-07.

Original reporting
SEC EDGAR · Dal Lago Marco
Published Aug 10, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 10, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STVN
Neutral
medium confidence
Mentioned
$STVN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STVNNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale by the CFO, including share count, price, and post-transaction holdings. It is primarily sentiment-related rather than a fundamental re-rating catalyst.

02

Market read

Traders may note the CFO sale for sentiment, but there is no accompanying operational or financial update in the filing text provided.

03

What to watch

The article does not state whether the sale was part of a broader pattern, whether options were exercised, or whether other insiders sold around the same time.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-10 after-hours; transaction dated 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for Stevanato Group S.p.A. (STVN).

Company-level read

Ticker impact

$STVNNeutralMedium confidence
Context

Stevanato Group CFO Dal Lago Marco filed a Form 4 selling 4,209 shares at $20.0900 on 2026-08-07.

Expected impact

Likely limited near-term impact; any reaction should be small and fade unless follow-on selling or other news emerges.

Evidence & confidence

The filing provides transaction size and price but no accompanying company-specific news, guidance, or legal/regulatory development.

Market effects

No clear sector read-through from a single CFO open-market sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be tax- or diversification-driven and may not signal reduced confidence, especially without any other negative company developments.

Key entities

  • Stevanato Group S.p.A.

    Company whose insider transaction was disclosed via Form 4.

  • Dal Lago Marco

    Chief Financial Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STVNHighAI 8/10

Stevanato Group Q3 Earnings Call Highlights

Stevanato Group (STVN) expects 2027 revenue growth to moderate to low-single-digit due to GLP-1-related headwinds, but believes growth will normalize beyond 2027. The company reaffirmed its 2026 guidance, forecasting revenue of €1.26B-€1.28B and adjusted EBITDA of €335M-€345.2M. It is ramping up manufacturing investments and working on over 50 GLP-1-related programs with 30 global customers.

$STVNMed

Stevanato (STVN) Q3 2026 Earnings Call Transcript

Stevanato (STVN) reported Q3 2026 earnings, with non-GLP biologics revenue up 30% offsetting GLP-1 declines. Full-year non-GLP biologics revenue rose 13%. The company expects lower GLP volumes in 2027 but strong demand in non-GLP biologics. They are backfilling revenue and expanding production capacity. Engineering segment results were below expectations, but BDS segment performance will offset this.

$STVNMed

Stevanato Group SpA (STVN) (Q3 2026) Earnings Call Highlights: Revenue Climbs 8%

Stevanato Group SpA (STVN) reported Q3 2026 revenue growth of 8%, but expects lower GLP-1 volumes in 2027 from a single customer, moderating growth. Engineering segment revenue declined 12%, and gross profit margin decreased to 29.1%. The company backfilled most GLP-1 shortfall but expects validation delays. Non-GLP biologics grew 30% in Q3, driven by broad engagement and capacity investments. Alina pen injector and other delivery devices are in validation stages.

$STVNMed

Stevanato Group S.p.A. (STVN): Financial results for Q3 2026

Stevanato Group S.p.A. (STVN) furnished an SEC Form 6-K — earnings release. EXHIBIT 99.1 Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 - The Company Maintains Fiscal Year 2026 Guidance - (PIOMBINO DESE, Italy) – November 3, 2026 – Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug de

HighAI 8/10

Why is Stevanato stock plunging today?

Stevanato Group's stock fell 25.5% to $14.71 after reporting Q3 2026 revenue of €326.1M, up 8% YoY, beating estimates. However, the outlook for 2027 revenue growth was cut to low single digits due to reduced GLP-1-related volumes from a large customer, alarming investors. The company maintained its full-year 2026 revenue guidance of €1.26B to €1.28B.